Clinical application evaluation and revision suggestions of clinical practice guideline on traditional Chinese medicine therapy alone or combined with antibiotics for community acquired pneumonia.
10.19540/j.cnki.cjcmm.20181009.006
- Author:
De-Min LI
1
;
Rui-Han QI
1
;
Hong-Chun ZHANG
1
;
Xing LIAO
2
;
Yan-Ming XIE
2
;
Jun-Hua ZHANG
3
;
Bo-Li ZHANG
3
Author Information
1. National Clinical Research Center for Respiratory Diseases, Center for Respiratory Diseases, the Department of Traditional Chinese Medicine Pulmonary Diseases, China-Japan Friendship Hospital, Beijing 100029, China.
2. Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
3. Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Guidelines;
antibiotics;
application evaluation;
clinical applicability;
community acquired pneumonia
- MeSH:
Anti-Bacterial Agents;
China;
Community-Acquired Infections;
drug therapy;
Drugs, Chinese Herbal;
Humans;
Medicine, Chinese Traditional;
Pneumonia
- From:
China Journal of Chinese Materia Medica
2018;43(24):4759-4764
- CountryChina
- Language:Chinese
-
Abstract:
To clarify the clinical application of the group standard (T/CACM 1035-2017) of the Chinese Society of Traditional Chinese Medicine (TCM), the clinical practice guideline on traditional chinese medicine therapy alone or combined with community acquired pneumonia, and to understand the clinical applicability of the Guideline. The clinical workers trained in terms of the Guideline in hospitals at all levels in China were selected as the research objects. A total of 494 questionnaires on application evaluation and 511 questionnaires on applicability evaluation were collected to construct the database of the post-effect evaluation of the Guideline. Excel software was used for statistical analysis. The overall evaluation of the Guideline was 92.31%, 91.06%, 87.45% respectively in efficacy, safety and economy. The Guideline was well used in clinical application, and 99.41% of the patients were willing to follow the recommended scheme. The agreed ratio in rationality evaluation was 97.98%, 92.37%, 94.53% and 92.71% in treatment rules, syndrome differentiation and classification, prevention of complications, and rehabilitation method. The effective rate of the prescriptions recommended in the Guideline was all above 65%. More than 80% of the prescriptions were Tanreqing Injection, Yinqiao Powder, Qingjin Huatan Decoction, Maxing Shigan Decoction, Shengmai San and Shashen Maidong Decoction. Adverse reactions, unknown active components and economy of Chinese patent medicines were the important factors affecting drug use and efficacy, providing a clinical basis for updating and revising the standard.
